Messenger Ribonucleic Acid (mRNA) Synthesis and Manufacturing Market Report 2025

The messenger ribonucleic acid (mRNA) synthesis and manufacturing market size has grown rapidly in recent years. It will grow from $4.56 billion in 2024 to $5.14 billion in 2025 at a compound annual growth rate (CAGR) of 12.7%. The growth seen during the historic period can be attributed to increased government investment in pandemic preparedness, the early success of COVID-19 mRNA vaccines, a growing emphasis on personalized medicine, a rising incidence of infectious diseases, and enhanced collaborations between biotechnology companies and academic institutions.

The messenger ribonucleic acid (mRNA) synthesis and manufacturing market size is expected to see rapid growth in the next few years. It will grow to $8.21 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The anticipated growth during the forecast period can be attributed to the expansion of therapeutic applications beyond vaccines, progress in mRNA delivery technologies, increased investments in biomanufacturing infrastructure, rising demand for rapid vaccine development platforms, and regulatory backing for accelerated approvals. Key trends expected during this period include a shift toward decentralized and modular mRNA production systems, integration of AI and automation into synthesis processes, development of thermostable mRNA formulations, advancement of circRNA technology, and the emergence of self-amplifying mRNA platforms.

The rising prevalence of infectious diseases is expected to drive growth in the messenger ribonucleic acid (mRNA) synthesis and manufacturing market. Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, and include illnesses like malaria that spread through direct or indirect contact. The increase in infectious diseases is linked to rapid urbanization, which results in higher population density and closer human interactions, facilitating the transmission of infections. mRNA synthesis and manufacturing contribute to combating these diseases by enabling the rapid development and scalable production of targeted vaccines and therapeutics that trigger specific immune responses. For example, in November 2023, the World Health Organization reported an estimated 249 million malaria cases worldwide in 2022, which was an increase of 5 million cases (2%) compared to 2021. Therefore, the growing incidence of infectious diseases is propelling the expansion of the mRNA synthesis and manufacturing market.

Technological advancements are also fueling the growth of mRNA manufacturing through the introduction of good manufacturing practice (GMP)-like platforms designed for preclinical development. Leading companies in the mRNA synthesis and manufacturing market are focusing on innovative solutions such as co-transcriptional capping platforms, which enhance mRNA stability, translation efficiency, and immunogenicity control by efficiently attaching protective caps to mRNA molecules during synthesis. For instance, in May 2025, GenScript, a US-based life sciences research tools company, launched a GMP-like mRNA manufacturing service. This scalable and regulatory-aware service is designed to produce high-purity, functional mRNA for investigational new drug (IND)-enabling preclinical studies, including toxicology, biodistribution, and pharmacokinetics or pharmacodynamics (PK or PD) assessments. The manufacturing process is conducted in cleanroom-compliant, ISO 7-classified environments and incorporates patented co-transcriptional capping technology. This service can deliver customized mRNA in as little as seven weeks and bridges the gap between research-grade and full GMP manufacturing, allowing early-stage biotech and pharmaceutical firms to conduct regulatory-aligned studies without incurring the high costs and delays typical of traditional GMP production.

In June 2024, BioNTech, a Germany-based biotechnology company, acquired CureVac for an undisclosed amount. This acquisition aims to combine CureVac’s proprietary mRNA technology, RNA printer platform, and clinical pipeline with BioNTech’s global infrastructure and development capabilities to enhance its position in infectious diseases and oncology. CureVac is a Germany-based biopharmaceutical company specializing in mRNA synthesis and manufacturing.

Major players in the messenger ribonucleic acid (mrna) synthesis and manufacturing market are Thermo Fisher Scientific Inc., Evonik Industries AG, Moderna Inc., BioNTech SE, AGC Biologics A/S, Eurofins Scientific SE, Lonza Group AG, Catalent Inc., WuXi Biologics (Cayman) Inc., Samsung Biologics Co Ltd., GenScript Biotech Corporation, Arcturus Therapeutics Holdings Inc., New England Biolabs Inc., CureVac N.V., Abzena plc, Creative Biolabs Inc., Aldevron LLC, eTheRNA immunotherapies NV, Bio-Synthesis Inc., TriLink BioTechnologies LLC.

North America was the largest region in the messenger ribonucleic acid (mRNA) synthesis and manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in messenger ribonucleic acid (mRNA) synthesis and manufacturing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the messenger ribonucleic acid (mRNA) synthesis and manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The messenger ribonucleic acid (mRNA) synthesis and manufacturing market consists of sales of synthetic deoxyribonucleic acid (DNA) templates, in vitro transcription kits, enzymes, nucleotides, purification systems, and formulation reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The messenger ribonucleic acid (mRNA) synthesis and manufacturing market research report is one of a series of new reports that provides messenger ribonucleic acid (mRNA) synthesis and manufacturing market statistics, including messenger ribonucleic acid (mRNA) synthesis and manufacturing industry global market size, regional shares, competitors with an messenger ribonucleic acid (mRNA) synthesis and manufacturing market share, messenger ribonucleic acid (mRNA) synthesis and manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the messenger ribonucleic acid (mRNA) synthesis and manufacturing. This messenger ribonucleic acid (mRNA) synthesis and manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Messenger ribonucleic acid (mRNA) synthesis and manufacturing is a biotechnological procedure centered on the large-scale design, production, and purification of mRNA molecules for application in vaccines and therapeutics. This process involves the enzymatic transcription of synthetic DNA templates into mRNA, followed by purification, formulation, and strict quality control measures to guarantee that the final mRNA product remains stable, effective, and safe for clinical or commercial use.

The primary categories of mRNA synthesis and manufacturing are mRNA drug synthesis and mRNA vaccine synthesis. mRNA drug synthesis involves the laboratory and industrial processes required to create, synthesize, and produce mRNA sequences designed for therapeutic purposes. These procedures occur at multiple operational stages, including preclinical, clinical, and commercial phases. Major therapeutic areas include infectious diseases, oncology, among others, with applications in vaccine development, therapeutic innovation, drug discovery, and other related fields.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.